

Section 2 of 7 - Institutional Perinatal Mortality Audit

2.1	Introduction	33
2.2	Recommendations and rationale	33
2.2.1	Implementation of the guideline	33
2.2.2	Perinatal mortality review committees	33
2.2.3	Review of a perinatal death	35
2.2.4	Data collection, documentation and reporting	35
2.2.5	Communication and feedback	36
2.2.6	Definitions for registration of births and perinatal deaths	37
2.3	References	38
Appe	ndix 1 Perinatal Mortaility Audit Package	40
Appe	ndix 2 Instructions on taking clinical photographs	51
Appe	ndix 3 Autopsy clinical summary form	54
Appe	ndix 4 Perinatal Mortality Classifications - quick reference sheet	55

SECTION 2 INSTITUTIONAL PERINATAL MORTALITY AUDIT

2.1 Introduction

The purpose of this section is to provide guidance for clinicians at maternity hospitals in the conduct of high quality audit of perinatal deaths to determine an accurate cause of death and issues surrounding the death for the purposes of discussion with the parents; planning of future pregnancies; practice improvement; and to improve the quality of data available for monitoring and research activities aimed at reducing perinatal death. Practice recommendations are supplemented by data collection forms and checklists in the Perinatal Mortality Audit Package (*Appendix 1*) to assist clinicians in implementing the guideline recommendations.

In the development of this section an attempt was made to obtain all existing national and international guidelines and protocols on perinatal mortality review. The following guideline/policy statements were used as a basis for development of this guideline:

- 1. Queensland Maternal and Perinatal Quality Council. Maternal and Perinatal Mortality Audit: Guidelines for Maternity Hospitals. Queensland: Queensland Government, Queensland Health; 2003⁽¹⁾.
- 2. NSW Health Department. Hospital Procedures for review and reporting of perinatal deaths. In; 2000⁽²⁾.
- 3. Perinatal Mortality Guidelines in British Columbia. Vital Statistics. In. Victoria, British Columbia; 1998⁽³⁾.

2.2 Recommendations and rationale

2.2.1 Implementation of the guideline

The PSANZ Clinical Practice Guideline for Perinatal Mortality Audit should be implemented in all institutions where births occur.

Strategies to assist in the uptake of the guideline into practice at the hospital level should be implemented. These strategies may include: identifying and addressing local barriers to uptake; ongoing structured and unstructured education for clinical staff including clinical leader advocacy; and implementing an audit and feedback mechanism on compliance with guideline reccommendations.

The implementation of best practice is often not simple and the lack of evidence for optimal approach to assist in this process remains elusive⁽⁴⁾. Although clinical practice guidelines are a promising tool in improving the quality of care, it is important for guidelines to be accompanied by a program for implementation and dissemination to ensure their use in clinical practice⁽⁵⁾. Although the evidence is unclear, interventions which may assist in the uptake of guidelines into practice include: professional education, audit and feedback, reminders and a multidisciplinary teams approach^(6, 7). The development of evidence-based practice support units within hospitals and clinical research implementation networks have been proposed as a means of effecting change to improve clinical care across the healthcare system⁽⁸⁾.

A recent survey of maternity hospitals in ANZ indicated less than optimal awareness and use of the guidelines⁽⁹⁾. The Australian and New Zealand Stillbirth Alliance and the PSANZ Perinatal Mortality Group have developed an educational program to aid in the implementation of the guidelines across Australia and New Zealand (www.stillbirthalliance.org/anz). It is hoped that this program will be used widely to address the problem of implementation.

2.2.2 Perinatal mortality review committees

(i) Format

A format for review of perinatal deaths needs to be developed in each institution, taking into account principles of confidentiality and impartiality. All perinatal deaths should be reviewed by the Perinatal Mortality Committee, including deaths of infants born within the service but who died elsewhere. Maternity services (particularly smaller hospitals) may choose to combine the functions of the perinatal mortality review committee with another hospital committee or regional mortality review committee.

(ii) Purpose

The functions of the Perinatal Mortality Committee should include:

- the review of all stillbirths and neonatal deaths:
- the classification of perinatal deaths according to the Perinatal Society of Australia and New Zealand (PSANZ)-Perinatal Death Classification (PDC) and Neonatal Death Classification (NDC);
- evaluation of the circumstances surrounding the death including a consideration of contributing factors; and
- on the basis of such considerations, the development of recommendations for improving the processes of care, ensuring feedback to clinicians;
- implementation of action required based on these recommendations;
- provision of a confidential case summary to the relevant agency within the jurisdiction's Health Department; and
- coordination of care for parents following a perinatal death, including follow-up.

(10) Membership:

The Perinatal Mortality Committee meetings should include multidisciplinary involvement, including those who are familiar with the circumstances of the perinatal death.

Membership of the Perinatal Mortality Committee should include representatives from: obstetrics, neonatology/paediatrics, pathology (preferably a perinatal/paediatric pathologist), midwifery, neonatal nursing, social workers, and other relevant medical specialists and allied health professionals.

Review by a multidisciplinary team has been shown to increase the yield from mortality review⁽¹¹⁾. Multidisciplinary involvement provides an opportunity for all members of the team providing care to participate in a comprehensive assessment of the standards of care and strategies for care improvement where necessary. Multidisciplinary perinatal death review is advocated by international groups⁽¹²⁾ and is incorporated in most Health Departments perinatal mortality review in Australia. Some Health Departments in Australia currently recommend multidisciplinary review by hospital committees^(1, 2) with some evidence of implementation⁽¹³⁾.

(iv) Protection for committee members

It is the responsibility of each institution's management to ensure that committee members and their deliberations are indemnified while undertaking this kind of audit on their behalf.

The aim of the perinatal mortality committee is to provide an atmosphere of confidence and security that will encourage health care providers and managers to communicate openly and honestly with their colleagues⁽¹⁴⁾. In order to do this, assurance should be sought by the administration of the institution that the information and discussion arising from the formal review cannot be used in legal proceedings. As mechanisms for establishing perinatal mortality committees with the appropriate protection differs across Australia and New Zealand (ANZ), committees should seek advice from their respective Health Departments.

(v) Timing of the review

The review should take place as soon as possible after the death, once results of core investigations are available.

The review should be undertaken in a timely manner so that it is within recent memory of those involved and also to enable information from the review to be incorporated into the discussion with the parents at the follow-up visit. The review should take place as soon as results are available from the initial investigations. A further review of the death by the mortality committee, once the results of all investigations are available, may be necessary to finalise the cause of death and to ensure further follow-up is arranged as required. Timely review of the death may also assist in providing counselling and support for staff.

2.2.3 Review of a perinatal death

(i) Cause of death and associated factors

The review should take place as soon as possible after the death, once results of core investigations are available.

The main cause of death and associated maternal/fetal/neonatal conditions, if present, should be classified according to the PSANZ-PDC for all perinatal deaths and in addition for all neonatal deaths and the PSANZ-NDC⁽¹⁵⁾.

(Please see Section 7 Perinatal Mortality Classifications for full details of the classifications and also Section 2; Appendix 4 for the Classification Quick Reference sheet.)

(ii) Potential contributing factors

The review of each perinatal death should include consideration to the presence of contributing factors in three main areas:

- maternal/social i.e. factors relating to the woman including her social situation;
- infrastructure/service organisation i.e. factors relating to the setting in which the care was provided; and
- professional care delivery i.e. factors relating to the clinical care provided.

The determination that contributing factors (also referred to as sub-optimal or avoidable factors) were present does not imply that the death could have been prevented if these factors were not present, rather that the risk of death may have been reduced.

Contributing factors can be classified by the type of factor: maternal/social; infrastructure/service organisation; and professional care delivery and may be further classified by timing: antenatal; intrapartum; and neonatal. This system is based on that described by the Confidential Enquiry into Stillbirths and Deaths in Infancy (CESDI)⁽¹²⁾ and later adapted for use in the EuroNatal study⁽¹⁶⁾. Sub-optimal care factors have been identified in approximately 30- 50% of stillbirths(17-20). Similarly, the EuroNatal study involving ten European countries showed sub-optimal factors were possibly or likely to have contributed to the death in about half of the 1619 perinatal deaths reviewed. Although there is limited information available in Australia on the contribution of sub-optimal care to perinatal death, the Consultative Council on Obstetric and Paediatric Mortality and Morbidity in Victoria reported the presence of *Suspected preventable factors in perinatal deaths* in approximately 30% of perinatal deaths⁽²¹⁾.

(Please see Section 2 Appendix 1.5 for a recommended format for review of contributing factors)

(iii) Other aspects of care - Communication and investigation

At review of each perinatal death, consideration should be given to the adequacy of communication with parents and between health care professionals and the investigations undertaken.

To ensure ongoing practice improvement, a review of the adequacy of communication around the time of death and investigations undertaken should be undertaken at the time of committee review of the death. CESDI identified sub-optimal care around the time of stillbirth in the following areas relating to communication and investigation: incomplete investigation of a stillbirth; staff not discussing the possibility of a post-mortem with parents, or not presenting adequate information about the different levels of examination which could be carried out; discussion about the post-mortem often undertaken by junior staff; not undertaking a post-mortem when consent was obtained and incompleteness of post-mortem reports. Bereavement support was also criticised. The report identified several cases where bereavement support was not provided and where written communication was described by the panel members as insensitive⁽¹²⁾.

2.2.4 Data collection, documentation and reporting

(i) Medical record

Clinicians should ensure that all relevant clinical details are documented clearly and accurately in the medical record at the time of the event and that all relevant documentation is completed according to local policy.

(ii) Death certificate

The Medical Certificate of Perinatal Death should be completed by, or under the supervision of, the Consultant responsible for care with due consideration to presence and significance of all perinatal conditions and complications. A revised Medical Certificate of Perinatal Death should be submitted, following review by the Perinatal Mortality Committee, where required.

The Royal College of Pathologists Australasia (RCPA) recommend that the death certificate be issued by the senior clinician responsible for care⁽²²⁾. As Perinatal Death Certificates are often issued prior to the results of an autopsy becoming available and, as perinatal autopsy may identify significant information about the cause of death⁽²³⁾, the completion of death certificates without consideration of autopsy findings may result in significant error in cause of death data⁽²⁴⁻²⁶⁾. Review by a multidisciplinary clinical group has also been shown to increase the value of post-mortem examination in determining an accurate cause of death. Therefore, it is essential that for all perinatal deaths the details on the death certificate are reviewed by the perinatal mortality committee including the full results of the autopsy when available⁽¹¹⁾.

As the process of revising the death certificate may differ across regions, it is recommended that all perinatal mortality committees become familiar with the process within their region and that a process is implemented to ensure that a revised death certificate is submitted when required.

(iii) Confidential clinical summary

A comprehensive confidential clinical summary should be completed for every perinatal death to facilitate local audit and, if required, forwarded to the relevant agency within the jurisdiction's Health Department.

A standardised data set should be collected for all perinatal deaths. This data set includes all significant family, medical and obstetric history; all major pregnancy complications including whether the pregnancy was terminated; and investigations undertaken around the time of the death including placental histopatholgy and autopsy.

The PSANZ Perinatal Mortality Audit Package (Section 2; Appendix 1) is recommended for data collection and perinatal mortality review.

2.2.5 Communication and feedback

(i) Feedback to clinicians

Notification of the death to the General Practitioner and other relevant care providers should be undertaken as soon as possible after the death. This should be followed by a comprehensive clinical summary promptly after review of the death.

A process of feedback to clinicians needs to be in place so that individual practices and hospital policy can be improved as a result of the review process. This includes standards in relation to perinatal mortality investigation, documentation and communication.

(ii) Follow-up consultation for parents

A follow-up consultation service should be provided for all parents following a perinatal death.

The follow-up meeting should involve the senior clinician who provided care and be scheduled at a suitable time after all relevant test results are available and following hospital perinatal mortality committee review where possible.

In cases of a congenital abnormality it may be appropriate to discuss the need for genetic counselling with a geneticist prior to the follow-up appointment with the senior clinician who provided care. The geneticist can then either attend the follow-up consultation or a further appointment can be offered at the time.

Depending on the results of the initial investigation, it may also be necessary to arrange further tests such as investigations for thrombophilia.

(Please see Section 5 Investigation of stillbirths and Section 6 Investigation of neonatal deaths for further details.)

2.2.6 Definitions for registration of births and perinatal deaths

The following definitions and examples are provided for clarification of the requirements for registration of births and perinatal deaths.

(i) Stillbirth (fetal death)

Death prior to the complete expulsion or extraction from its mother of a product of conception of 20 or more completed weeks of gestation or of 400 gms or more birthweight. The death is indicated by the fact that after such separation the fetus does not breathe or show any other evidence of life, such as beating of the heart, pulsation of the umbilical cord, or definite movement of voluntary muscles.

A Perinatal Death Certificate is required by the Australian Bureau of Statistics (ABS) for all stillbirths according to the above definition. This definition applies regardless of the known or presumed timing of the death in utero. Examples are provided here of circumstances which may require clarification.

Example 1: Fetus papyraceus

In the case of a birth after 20 weeks gestation where the birth weight is less than 400 gms and where the Intrauterine Fetal Death (IUFD) may have occurred some time before the birth, the birth is considered a stillbirth except in the case of fetus papyraceus where the fetus is not readily recognisable.

Example 2: Multiple pregnancy

In the case of a twin pregnancy with an IUFD of Twin 1 at 19 weeks and spontaneous onset of labour and delivery at 23 weeks gestation where Twin 2 is live born weighing 550 gms and Twin 1 weighs 200 gms, Twin 1 is registered as a stillbirth and Twin 2 as a livebirth.

In the case of a twin pregnancy with a fetal death and spontaneous delivery of Twin 1 at 19 weeks weighing 200 gms and subsequent fetal death and delivery of Twin 2 at 21 weeks weighing 300 gms, Twin 1 is not required to be registered, however Twin 2 is.

(ii) Neonatal death

Livebirth: A livebirth is the complete expulsion or extraction from its mother of a product of conception, irrespective of the duration of the pregnancy, which after such separation, breathes or shows any other evidence of life, such as beating of the heart, pulsation of the umbilical cord, or definite movement of voluntary muscles, whether or not the umbilical cord has been cut or the placenta is attached; each product of such a birth is considered liveborn⁽⁽²⁷⁾⁾.

Neonatal death: is defined as death of a liveborn baby within 28 days of life.

A Perinatal Death Certificate is required by the ABS for all neonatal deaths according to the above definition. This definition applies regardless of the birthweight or gestational age and also for resuscitated stillbirths.

Example 1: Resuscitated stillbirth

Where an infant is stillborn and, following active resuscitation, a heart beat is detected, the birth is required to be registered as a livebirth. If the infant subsequently dies up to 28 days of age registration as a neonatal death is necessary.

2.3 References

- 1. Queensland Maternal and Perinatal Quality Council. Maternal and perinatal mortality audit: Guidelines for maternity hospitals. Queensland: Queensland Government, Queensland Health; 2003 Contract No.: Document Number.
- 2. NSW Health Department. Hospital Procedures for review and reporting of perinatal deaths. Electronic source http://www.health.nsw.gov.au/fcsd/rmc/cib/circulars/2002/cir2002-6.pdf; 2002 January Contract No.: Document Number|.
- 3. British Columbia vital statistics agency. Vital Statistics. Victoria; 1998 http://www.vs.gov.bc.ca/.
- 4. Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients' care. Lancet. 2003 Oct 11;362(9391):1225-30.
- 5. Grol R. Successes and failures in the implementation of evidence-based guidelines for clinical practice. Med Care. 2001 Aug;39(8 Suppl 2):II46-54.
- 6. Grimshaw JM, Eccles MP. Is evidence-based implementation of evidence-based care possible? Med J Aust. 2004 Mar 15;180(6 Suppl):S50-1.
- 7. Cretin S, Farley DO, Dolter KJ, Nicholas W. Evaluating an integrated approach to clinical quality improvement: clinical guidelines, quality measurement, and supportive system design. Med Care. 2001 Aug;39(8 Suppl 2):II70-84.
- 8. Robinson JS, Turnbull DA. Changing healthcare organisations to change clinical performance. Med J Aust. 2004 Mar 15;180(6 Suppl):S61-2.
- 9. Flenady V, MacPhail J, Mahomed K, Chadha Y, Charles A, Jennings B, et al., editors. Uptake of the PSANZ Perinatal Mortality Audit Guidelines: A survey of midwives and obstetricians in Australia and New Zealand. Perinatal Society of Australia and New Zealand Congress; 2007; Melbourne.
- 10. Hueston W, Mainous III A, Farrell B. A cost-benefit analysis of smoking cessation programs during the first trimester of pregnancy for the prevention of low birthweight. Journal of Family Practice. 1994;39(4):353 (5).
- 11. Brodlie M, Laing IA, Keeling JW, McKenzie KJ. Ten years of neonatal autopsies in tertiary referral centre: retrospective study. BMJ. 2002 Mar 30;324(7340):761-3.
- 12. CESDI Confidential Enquiry into Stillbirths and Deaths in Infancy. 8th Annual Report. London: Maternal and Child Health Research Consortium; 2001 Contract No.: Document Number.
- 13. Flenady V, Woodgate P, Kilgour C, Hockey R, Tudehope D, editor. Perinatal Mortality Survey. Proceedings Perinatal Society of Australia and New Zealand 5th Annual Congress; 2001 March 2001; Canberra.
- 14. NSW Health Department. The clinicians toolkit for improving patient care. Sydney: NSW Health Department; 2001 [updated 2001; cited 2004]; Available from: http://www.health.nsw.gov.au/qulaity/qual_privilege.htm.
- 15. Chan A, King JF, Flenady V, Haslam RH, Tudehope DI. Classification of perinatal deaths: development of the Australian and New Zealand classifications. J Paediatr Child Health. 2004 Jul;40(7):340-7.
- 16. Richardus JH, Graafmans WC, Bergsjo P, Lloyd DJ, Bakketeig LS, Bannon EM, et al. Suboptimal care and perinatal mortality in ten European regions: methodology and evaluation of an international audit. J Matern Fetal Neonatal Med. 2003 Oct;14(4):267-76.
- 17. CESDI Confidential Enquiry into Stillbirths and Deaths in Infancy. 5th Annual Report. London: Maternal and Child Health Research Consortium; 1998 Contract No.: Document Numberl.
- 18. CESDI Confidential Enquiry into Stillbirths and Deaths in Infancy. 6th Annual Report. London: Maternal and Child Health Research Consortium; 1999 Contract No.: Document Number|.
- 19. De Lange TE, Budde MP, Heard AR, Tucker G, Kennare R, Dekker GA. Avoidable risk factors in perinatal deaths: a perinatal audit in South Australia. Aust N Z J Obstet Gynaecol. 2008 Feb;48(1):50-7.
- 20. Saastad E, Vangen S, Froen JF. Suboptimal care in stillbirths a retrospective audit study. Acta Obstet Gynecol Scand. 2007;86(4):444-50.
- 21. CCOPMM. Annual Report for the Year 2000. Melbourne: The Counsultative Council on Obstetric and Paediatric Mortality and Morbidity; 2003 Contract No.: Document Number|.
- 22. Royal College of Pathologists of Australasia. The decline of the hospital autopsy: a safety and quality issue for healthcare in Australia. Med J Aust. 2004 Mar 15;180(6):281-5.
- 23. Godijn SJ EJ, Khong Y. Value of the perinatal autopsy: critique. Pediatric and Developmental Pathology. 2001;5:480-8.
- 24. Cartlidge PH, Dawson AT, Stewart JH, Vujanic GM. Value and quality of perinatal and infant postmortem examinations: cohort analysis of 400 consecutive deaths. BMJ. 1995 Jan 21;310(6973):155-8.
- 25. Duley LM. A validation of underlying cause of death, as recorded by clinicians on stillbirth and neonatal death certificates. Br J Obstet Gynaecol. 1986 Dec;93(12):1233-5.

- 26. Kirby RS. The coding of underlying cause of death from fetal death certificates: issues and policy considerations. Am J Public Health. 1993 Aug;83(8):1088-91.
- 27. World Health Organisation. Making pregnancy safer: Report by the secretariat: World Health Organisation; 2002 5 December. Report No.: EB107/26 Contract No.: Document Number.
- 28. Flenady V, MacPhail J, Mahomed K, Chadha Y, Charles A, Jennings B, Jeffery H, Harvey B, Waters K, Gray P; for the PSANZ Perinatal Mortality Group. Uptake of the Perinatal Society of Australia and New Zealand (PSANZ) perinatal mortality audit guidelines: A survey of midwives and doctors in Australia and New Zealand. Proceedings Perinatal society of Australia and New Zealand 10th Annual Congress, Melbourne, April 20

Perinatal Mortality Audit Package



Perinatal Mortality Group http://www.psanz.org.au

- 1.1 Stillbirth investigations
- 1.2 Neonatal death investigations
- 1.3 Accoucheur placental examination and preparation for pathology
- 1.4 Clinical examination of baby checklist
- 1.5 Perinatal mortality confidential case summary
 - Part a Perinatal death clinical summary
 - Part b Perinatal Mortality Committee review

1.1 Stillbirth investigations

CORE INVE		
Performed At diagnosis of IUFD Yes/No Comments/Results Please place √(Yes) or X (No) in boxes provided Mother		Maternal Sticker (Inc Name, DOB, UR, Address, Telephone Number)
Medical & obstetric history See Appendix 1.5 Ultrasound	Baby Clinical examination Abnormal See Appendix 1.4	
Amniocentesis Performed	Clinical photographs See Appendix 2 Babygram Swabs of ear & throat	
Sample for chromosomes	Autopsy	Singleton Multiple Baby number (e.g. Twin 1)
Vaginal culture Low vaginal/Peri-anal	Not approached	FURTHER INVESTIGATIONS
culture	Partial Full Genetic autopsy Results	Performed Date/ 8-12 weeks Postpartum Yes/No Results Please place √ (Yes) or X (No) in boxes provided
Group & antibody screen Kleihauer	Cord/Cardiac blood samples Full blood count with smear (nucleated red count)	Thrombophilia Anticardiolipin antibodies
CMV	Placenta, membranes and cord Macroscopic examination See Appendix 1.3 Placental swabs for Microbiology Biopsy of placenta & amnion for chromosomal analysis Placental histopathology.	Prothrombin G20210A
APC resistance		Comments
Other	Other	Signature
Signature Date/	Signature Date/	Date/

1.2 Neonatal death investigations

AT BIRTH OF HIG		
Performed Comments/Results Yes/No Please place √ (Yes) or X (No) in boxes provided	Performed Yes/No Comments/Results Please place √ (Yes) or X (No) in boxes provided	Maternal Sticker
Mother Medical & obstetric history See Appendix 1.5 Vaginal culture Low vaginal/Peri-anal culture	Baby Clinical examination	(Inc Name, DOB, UR, Address, Telephone Number)
Blood tests Full blood exam	Autopsy	Singleton Multiple Baby number (e.g. Twin 1)
Kleihauer	Not approached	FURTHER INVESTIGATIONS
Renal function	Refused	8-12 weeks Postpartum Performed Comments/ Yes/No Results Please place √ (Yes) or X (No) in boxes provided
CMV	Cord blood sample Full blood count with smear (nucleated red count)	Thrombophilia Anticardiolipin antibodies
APC resistance	Other bloods Group DCT	Protein S deficiency
Other	Other	Comments
Signature Date//	Signature	Signature
	Date/	Date/

1.3 Accoucheur placental examination and preparation for pathology

Please complete details as required

Maternal Sticker

(Inc Name, DOB, UR, Address, Telephone Number)

	Step 1 Placental cultures						
•		Using aseptic technique and	being careful				
	not to	cross contaminate, swab in betwee		on.			
Step 2	Accoucheur	examination of the placenta, mer	mbranes and cord usi	ng sterile gloves			
•							
Cord insertion (Circle)		entral / Marginal / Velamentous / Oth					
Cord appearance (Circle		Meconium Stained / Other					
No of cord vessels		Total cord length	cm	Cord knots (Circle)	Yes / No		
Placental dimensions	cm	Placental weight	•	Placental odour			
Maternal surface (Circle	all that apply)	Intact / Incomplete / Gritty / Fatty	y Infarcts / Retroplacent	tal Clot / Succenturiate /			
		Circumvallate / Bipartite					
Ston 2	-	iaana aamuling fay ahyamaaay	nal analysis				
Step 3	Tissue sampling for chromosomal analysis						
Prior to ser	iding the placenta	to pathology, a sample of umbilical o	cord should be collected	d using aseptic technique	as outlined		
	Prior to sending the placenta to pathology, a sample of umbilical cord should be collected using aseptic technique as outlined below. If there are any clinical indications of placental mosaicism, then a placental sample may be required as well						
	➤ Collect a 1cm³ sample of the middle of the umbilical cord, using a sterile surgical knife and dissecting forceps.						
➤ Colle	➤ Place in either a designated cytogenetics bottle or a sterile container, with either sterile saline solution or Hank's						
	s in either a design	ated cytogenetics bottle or a sterile	container with either e	tarila calina calution or Ha	nv'e		
➤ Place		nated cytogenetics bottle or a sterile bottle and label with maternal name					

Step 4 Send Placenta, Membrane and Cord to the Pathology fresh and unfixed for histopathological examination

1.4 Clinical examination of baby checklist

Please tick appropriate box and complete details as required

Maternal Sticker

Baby measurements 1. Crown – heel (stretched) cms 2. Head circumference cms 3. Weight gms	(IIIC Name, DOB, OR, 7	Address, Telephone Number)
If Stillbirth Estimated date of IUFD:/	Singleton Multiple Baby number	(e.g. Twin 1)
Maceration degree Fresh; no skin peeling	NECK Normal	LIMBS Length Normal Short Long If Short, what segments seem short Form Nemed Asymmetric Missing parts
changes or decomposition	CHEST Normal Long & narrow Short & broad Other	Normal Asymmetric Missing parts If other, describe:
HEAD AND FACE Head Relatively normal Collapsed Anencephalic Hydrocephalic Mydrocephalic If abnormally shaped, describe:	If Spina bifida, describe: ABDOMEN Normal	Length Appearance: Normal Abnormal If abnormal, describe:
Eyes	Omphalocele Gastroschisis BACK Normal Spina bifida	Number present:
Normal Prominent Sunken Straight Far apart Close together Upslanting Downslanting	If Spina bifida, describe:	Unusual form of fingers Unusual position of fingers Abnormal webbing or syndactyly
Globes normal Absent Eyes very small Very large	Scoliosis Kyphosis Other	If abnormal, describe
Lens opacity Corneal opacity Syelids fused Other If other, describe:	If other, describe:	Thumbs Number present:
Nose	Anus Normal	Unusual position Looks like a finger If abnormal, describe
Normal Abnormally small Asymmetric Abnormally large Nostrils Apparently patent Obstructed Single nostril Other	Gender Male	Finger nails All present
If other, describe:	Normal Very small Hypospadias Chordee Hypospadias, level of opening	FEET Appearance Normal Abnormal If abnormal, describe
Mouth Normal size	Scrotum	Toes Number present: If not 5+ 5 describe
Left Right Midline Midline	Testes Descended Undescended Other	Spacing: Normal Abnormal If abnormal, describe
Intact Cleft Mandible Normal Large Small Other	If other, describe:	All present
Small Other If other, describe:	Urethral opening Present Absent/unidentifiable Vaginal introitus Present Absent/unidentifiable	Revised gestational age
Ears Normal Preauricular tags Lowset Preauricular pits Other Posteriorly rotated If other, describe:	Clitoris Present Unidentifiable Inlarged Other If other, describe: Ambiguous sex	Examined by:(Print name) Date: Summary of key findings:

1.5 Perinatal mortality confidential case summary Part A - Clinical summary **Maternal Sticker** Form to be completed by Hospital of birth Please tick appropriate box and complete details as required (Inc Name, DOB, UR, Address, Telephone Number) Maternal details Country of birth: Ethnicity: Singleton Multiple Baby number..... (e.g. Twin 1) Education: <High school ☐ High school completed ☐ Tertiary completed ☐ Husband/Partner Occupation: Mother..... De facto \square Widowed \square Marital Status: Never married Married Divorced Separated Medical and obstetric history (Details) (Details) Venous thromboembolism $\ \square$ Hypertension Family history Congenital abnormalities Diabetes Other relevant Cervical surgery Venous thromboembolism Uterine abnormality Maternal medical history Other Details Previous pregnancy outcomes (numbers) Miscarriages Terminations Stillbirths Live births Neonatal deaths Postnatal deaths **Obstetric history** Delivery Baby Birth Baby (Include details of congenital DOB abnormalities and cause of death) GA method Complications number Sex weight outcome Current pregnancy Maternal transfer: Gravida Parity Antenatal Postnatal Singleton Multiple \square During labour **Plurality** (Number) **Public** Private Date and time of transfer...../.....; Charge status Hospital transferred from Adverse social factors Reason Type of antenatal care No antenatal care Hospital clinic General practitioner (GP) Birth centre Home birth midwife \Box Obstetrician/Midwife (Private) GP/Midwife Other Intended place of birth Maternal height Maternal weight at booking visit. BMI Antenatal medications Diet Vegan \square Corticosteroids **Tocolytics** Vegetarian Normal Folic acid Dietary supplement Please state - Not stated **Antibiotics** - None - < 24 hrs prior to baby's birth Methadone - Complete - Dosing - > 7 days before baby's birth Other Please state Substance use Tobacco Smoking Alcohol Other Average number of cigs At first visit П - Never smoked П Cannabis П **Amphetamines** Nil - Quit in last 12 months Number per day Units per day Heroin Cocaine - Quit before 1st visit Occasional smoker (<1 Per Day) Units per week Hallucinogens Ecstasy - Smoker Unknown Smoking at time of birth Yes □ No □ Unknown \square - Unknown

1.5 Perinatal mortality confidential case summary **Maternal Sticker** (Inc Name, DOB, UR, Address, Telephone Number) Part A - Clinical summary continued Please place $\sqrt{\text{(Yes)}}$ or X (No) in boxes provided Antenatal (AN) EDC by USS/..... EDC by LMP/..... Assisted conception Type Morphology USS $\ \square$ Gest Total No. USS Gestation at 1st antenatal visit Total No. of antenatal visits..... Screening/Diagnostics/Monitoring - Chorionic villus sampling - CTG Glucose screen П П - Nuchal translucency - Doppler studies Cervical suture - Amniocentesis - Group B strep screen Other diagnostics/procedures - Cordocentesis - Vaginal culture (HVS) Medical conditions and pregnancy complications Diabetes Hypertension Twin twin transfusion Antepartum haemorrhage - Pre-existing - Chronic hypertension: essential - Placental abruption Threatened preterm labour - Gestational - Chronic hypertension: secondary \square - Placenta praevia Oligohydramnios П П SLE - Chronic hypertension: unspecified \square - Vasa praevia Polyhydramnios П П П Cardiac disease - Gestational hypertension - Other APH Anaemia Renal disease - Pre-eclampsia - APH or undetermined origin Urinary tract infection П Asthma - Pre-eclampsia superimposed Cervical incompetence Asymptomatic bacteriuria Epilepsy on chronic hypertension Bleeding < 20 wks GBS vag culture positive П П Fetal growth restriction - Unspecified hypertension Prelabour ROM Maternal injury Duration MR Wks..... Days П Cervical surgery - Max systolic Max diastolic....... Other fetal abnormalities Hrs Unknown Other **Labour and Delivery Labour onset** Spont ☐ Induced ☐ No labour ☐ **Labour duration** (hrs/mins) 1st stage/..... 2nd stage/..... Fetal monitoring Amniotic fluid Clear ☐ Meconium ☐ Nil ☐ Induction reason Intermittent auscultation **Induction method** Oxytocin □ ARM \square Other Prostaglandis Cardiotocography Method of delivery..... Labour complications - On admission п П Spont vag Vacuum Fetal distress - Intermittent intrapartum Chorioamnionitis C.S. emerg C.S. elect. PPH - Continuous External Internal Forceps - Clinical signs - Placental pathol Fetal scalp pH Lowest record . Reason for Operative Delivery..... Date and time/..... Presentation Cephalic ☐ Breech ☐ Other ☐ Please state Other Analgesia None ☐ Nitrous oxide ☐ IMI narcotic ☐ Epidural ☐ Spinal ☐ Other Anaesthesia None ☐ General ☐ Spinal ☐ Epidural ☐ Pudendal \square Other \square Relevant obstetric events summary Gestation **Event** Date

Part A - Clinical summary continued

Please complete Clinical Examination of Baby Form (Appendix 1.4)

Maternal	l Sticker		

Baby Details						
UR number:				Birth order		Sex Male ☐ Female ☐ Undetermined ☐
Gestational age Place of birth			. days	Birthweight	-	Date & Time of birth:/;
Type of death:		-				If yes estimated date of death/
. •	 nin			IPPV - bag and mas		PV - intubation ☐ External cardiac massage ☐
Who performe	d resusci	tation? Not o	done 🔲 Neona	tologist 🔲 Pa	aediatrician	Obstetrician Neonatal nurse
Neonatal Regis	strar \square	Paediatric	Registrar D Obstet	tric Registrar 🛚	Midwife L	Other
Resuscitation	medicatio	ons None \square	Narcotic antagonist	Sodium bicarb	onate \square	Adrenaline Other
	r admission	n No □	Hospital transf	erred to:		■ Mech. Vent Yes ■ ■ Mech. Vent Yes ■ No ■
Relevant nec					,	,,
Date	Time	Postnatal age	Event			

Part B - Perinatal Mortality Committee review

Please tick appropriate box and complete details as required

Maternal Sticker

5.	Termination of pregnancy Was the pregnancy terminated? Yes □ No □ Fetal abnormality □ Maternal psychosocial reasons (pre-via	If yes, was the pregnancy terminated due to: ble) Maternal medical condition (pre-viable)
4.	Fetal / Neonatal infection Did infection contribute to the death? Yes □ No □	If yes state organism Culture site
3.	Congenital abnormality Was congenital abnormality present? Yes □ No □ Unknown □ If yes, please state abnormality:	If unknown, are results of investigations pending? Yes □ No □ If yes, please state tests awaiting:
	b. Neonatal Death Classification (PSANZ-NDC) Category No. Category description	b. Neonatal Death Classification (PSANZ-NDC) Category No. Category description
2. (i)	Classification of associated conditions Perinatal Mortality Classifications associated conditions 1 a. Perinatal Death Classification (PSANZ-PDC) Category No. Category description:	(ii) Perinatal Mortality Classifications associated conditions 2 a. Perinatal Death Classification (PSANZ-PDC) Category No. Category description:
	e. Other relevant circumstances	
	-	
(ii)	Cause of death recorded on Medical Certificate a. Main disease or condition in fetus or infant:	
	Category No. Category description:	
	Category Description: Neonatal Death Classification (PSANZ-PDC)	
(i)	PSANZ Perinatal Mortality Classification cause of death a. Perinatal Death Classification (PSANZ-PDC) Category No.	
1.	Classification of Cause of Death	

Part B - Perinatal Mortality Committee review continued

Please tick appropriate box and complete details as required

Maternal Sticker

6.	Factors relating to care	
----	--------------------------	--

) Po We	entially contributing factors: e any potentially contributing factors relating to care access or provision thought to be present? Yes splease complete below:	No 🗆							
,	Factor		Timing						
(a)	Factors relating to the woman/ her family/ social situation: Yes	Antenatal	Intrapartum	Postnata					
	Factor 2:								
(b)	Factors relating to access to care: Yes No								
	Factor 1:								
	Factor 2:								
(c)	Factors relating to professional care: Yes No								
	Factor 1:								
	Factor 2:								
We	re any areas identified for practice improvement Yes No								
•	es, please complete Practice Improvement Recommendations below.								
Act	on required: Person responsible:								
<u>Re</u>	ommendation 2:								
	Action required: Action to be reviewed by (date): / / Person responsible:								
<u>Re</u>	Recommendation 3:								
	on required: Person responsible: Person responsible:								
. Ot	ner discussion relevant to practice improvement or educational aspects								
				•••••					

Part B - Perinatal Mortality Committee review continued

Please tick appropriate box and complete details as required

Maternal Sticker

9. Follow-up visits for	parents		
Obstetrician:			Date arranged: /
Neonatologist:			Date arranged: /
General Practitioner:			Date arranged: /
Other			
GP notified of the death?	Yes \square	No \square	Date General Practitioner was notified
Genetic counselling required?	Yes \square	No \square	Date arranged: / /
Further investigations required?	Yes \square	No \square	If yes, please state
Date of committee review / .	/es 🗆		
If yes, date finalised: /	/		
Name of person completing this for	m:		
Phone number:			
Signed			

Section 2; Appendix 2 Instructions on taking clinical photographs

High quality medical photographs are preferred; however, Polaroid pictures are better than no pictures at all. Ideally digital photographs should be taken which will allow the clinician to check each photograph after it is taken. These photographs should be taken in addition to bereavement photographs.

Consent:

Parental consent is necessary prior to taking clinical photographs. Due to their clinical nature it is strongly recommended that the parents are not offered copies, but specific bereavement photographs are taken instead.

Background:

Plain white or surgical drapes (other backgrounds may create glare or alter skin tone).

Scale:

- Place a paper tape measure next to the baby (a plastic ruler will create glare)
- Ensure zero is aligned at the base of the foot or crown of the head.
- Use sticky tape to ensure the tape is straight; and
- Measure should be on the bottom of the frame or the left.

Identification:

Write the baby's UR number on the paper tape measure for identification.

Don't write any other identifying information in case the photographs are ever mislaid.

Settina:

Photographs should be taken in a private area away from the parents.

Technique:

The photographs should be taken from directly above the baby. Consequently it is best to place the baby on the floor, in order to get sufficient height above the baby.

Magnification:

Use a 50 mm lens/magnification for the whole body photographs, and maintain a consistent distance. Use a 100 mm lens/magnification (except for digital) for the facial photographs, filling the whole frame.

Baby:

The baby should be naked for all the photographs.

Position:

- AP view whole body frontal including limbs
- PA view whole body back including limbs
- Lateral view of the body
- Lateral views of the face
- Frontal view of the face
- Photographs of any abnormalities

Section 2; Appendix 2 Instructions on taking clinical photographs continued

AP View – Whole body frontal including limbs

PA View – Whole body back including limbs



- Tape measure to the left
- Palms facing up



- Keep the baby in this position for the minimum time possible.
- Tape measure to the left
- Palms facing down





To stabilise:

- Pull underneath arm forwards
- Legs in 'running position'
- Top arm and leg will fall forward which will aid stability.
- Keep the tape measure to the left

Frontal view of the face



Ensure tape measure is in the frame

Page 2 of 3

Section 2 Appendix 2 Instructions on taking clinical photographs continued

Lateral views of the face





• Keep tape measure to the left of the frame to aid easy identification of the side being viewed.

If there are any specific abnormalities these should be photographed individually, with a scale in view and the photograph labelled with the baby's UR number.

Section 2; Appendix 3 Autopsy clinical summary form

Please attach the following:

- copy of the death certificate;
- copies of all antenatal ultrasound reports; and
- copy of amniocentesis report if available

Maternal Sticker

Baby Details	Singleton Multiple Baby number (e.g. Twin 1)
UR number:Sex Male Female Undetermined	& Time of birth:/;
Type of death: Fetal ☐ Antepartum death Unknown ☐ No ☐/	Yes ☐ — If yes estimated date of death
Neonatal (NND) ☐ → → Death Certificate completed Yes ☐ No ☐	NND date & time of death:/;
Treatment or condition likely to cause hazard at autopsy	
Hepatitis B Pos ☐ Tuberculosis ☐ Specify	HIV (Aids Virus) □ Other □
Clinical summary (including details to be clarified at autopsy)	
Provisional clinical diagnosis (to be completed by physician 1	requesting autopsy)
2	
Please list doctors to receive report	
Name 1	Address
Clinical contact(Please print)	Telephone
Signature (person completing this form)	Date
Print name	

Section 2; Appendix 4 Perinatal Mortality Classifications - quick reference sheet

PSANZ-PDC Congenital Abnormality (including terminations for congenital abnormalities) 1.1 Central nervous system 1.2 Cardiovascular system 1.3 Urinary system 1.4 Gastrointestinal system 1.5 Chromosomal Metabolic 1.7 Multiple/non chromosomal syndromes Other congenital abnormality 1.81 Musculoskeletal 1.82 Respiratory 1.83 Diaphragmatic hernia Haematological 1.84 1.85 Tumours 1.88 Other specified congenital abnormality 1.9 Unspecified congenital abnormality Please note that terminations of pregnancy for perinatal deaths within this category should be identified by the inclusion of an "09" for two-digit codes and a "9" for the three digit codes Perinatal Infection 2.1 Bacterial 2.11 Group B Streptococcus 2.12 E coli 2.13 Listeria monocytogenes 2 14 Spirochaetal eg Syphilis 2.18 Other bacterial 2.19 Unspecified bacterial 2.2 Viral 2.21 Cytomegalovirus 2.22 Parvovirus 2.23 Herpes simplex virus 2.24 Rubella virus 2.28 Other viral 2.29 Unspecified viral 2.3 Protozoal eg Toxoplasma 2.5 Fungal 2.8 Other specified organism Other unspecified organism 2.9 Hypertension 3.1 Chronic hypertension: essential Chronic hypertension: secondary, eg renal disease Chronic hypertension: unspecified 3.4 Gestational hypertension 3.5 Pre-eclampsia 3.51 With laboratory evidence of thrombophilia Pre-eclampsia superimposed on chronic hypertension 3.61 With laboratory evidence of thrombophilia 3.9 Unspecified hypertension Antepartum Haemorrhage (APH) 4.1 Placental abruption 4.11 With laboratory evidence of thrombophilia 4.2 Placenta praevia 4.3 Vasa praevia 4.8 Other APH 4.9 APH of undetermined origin Maternal Conditions Termination of pregnancy for maternal psychosocial indications Diabetes / Gestational diabetes Maternal injury 5.31 Accidental 5.32 Non-accidental 5.4 Maternal sepsis

5.5 Antiphospholipid syndrome

Obstetric cholestasis

5.8 Other specified maternal conditions

_	Cic	1551	ilcations - quick reference s			
	Speci	fic Peri	natal Conditions			
	6.1	Twin-tv	win transfusion			
	6.2	Fetoma	aternal haemorrhage			
	6.3	Antepa	artum cord complications			
			ord haemorrhage			
			rue knot with evidence of occlusion			
		6.38 O				
			nspecified			
	6.4		e abnormalities, eg bicornuate uterus, cervical			
	0.4		petence			
	6.5		auma (typically infants of >24 weeks gestation or			
	0.0		birthweight)			
	6.6		nune disease			
	0.0	6.61	Rhesus			
		6.62	ABO			
		6.63				
			Alloimmune thrombocytopenia			
		6.68	Other			
		6.69	Unspecified			
	6.7		hic hydrops			
	6.8		specific perinatal conditions			
			Rupture of membranes after amniocentesis			
			Termination of pregnancy for suspected but			
			unconfirmed congenital abnormality.			
			Fetal subdural haematoma			
			Other			
	6.9	Unspe	cified			
			partum Death (typically infants of >24 weeks			
		tion or	>600g birthweight)			
	7.1		trapartum complications			
		7.11	Uterine rupture			
		7.12	Cord prolapse			
		7.13	Shoulder dystocia			
		7.18	Other			
	7.2	Eviden	ice of non-reassuring fetal status in a normally grown			
		infant (eg abnormal fetal heart rate, fetal scalp pH/lactate,			
			ulse oximetry without intrapartum complications)			
	7.3		apartum complications and no evidence of non-			
			ring fetal status.			
7.9 Unspecified hypoxic peripartum death						
	Fetal	Growth	Restriction (FGR)			
	8.1	With evidence of reduced vascular perfusion on Doppler				
		studies and /or placental histopathology (eg significant				
		infarction, acute atherosis, maternal and/or fetal vascular				
		thromb	osis or maternal floor infarction)			
	8.2	With chronic villitis				
	8.3	No pla	No placental pathology			
	8.4		No examination of placenta			
	8.8		specified placental pathology			
	8.9	Unspecified or not known whether placenta examined				
	Spon	taneou	s Preterm (<37 weeks gestation)			
9.1 Spontaneous preterm with intact membranes, or						
			ane rupture <24 hours before delivery			
		9.11	With chorioamnionitis on placental histopathology			
		9.12	Without chorioamnionitis on placental			
		0.12	histopathology			
		9.13	With clinical evidence of chorioamnionitis, no			
		0.10	examination of placenta			
		9.17	No clinical signs of chorioamnionitis, no			
		3.17	examination of placenta			
		9.19				
		9.19	Unspecified or not known whether placenta			
	0.2	examined				
	9.2		neous preterm with membrane rupture ≥24 hours			
			delivery			
		9.21	With chorioamnionitis on placental histopathology			
		9.22	Without chorioamnionitis on placental			
		0.00	histopathology			
		9.23	With clinical evidence of chorioamnionitis, no			
			examination of placenta			
		9.27	No clinical signs of chorioamnionitis, no			
			examination of placenta			
		9.29	Unspecified or not known whether placenta			
			examined			

	duration before delivery					
9.3						
9.3	Without chorioamnionitis on placental histopathology					
9.3	With clinical evidence of chorioamnionitis, no					
	examination of placenta					
9.3	No clinical signs of chorioamnionitis, no examination					
	of placenta					
9.3						
Une	xplained Antepartum Death					
10.	With evidence of reduced vascular perfusion on					
	Doppler studies and /or placental histopathology (eg					
	significant infarction, acute atherosis, maternal and/or					
	fetal vascular thrombosis or maternal floor infarction)					
10.						
10.						
	No examination of placenta					
10.						
10.						
10.	onspecified of flot known whether placenta examined					
No	Obstetric Antecedent					
11.						
	11.11 SIDS Category IA: Classic features of SIDS					
	present and completely documented.					
	11.12 SIDS Category IB: Classic features of SIDS					
	present but incompletely documented.					
	11.13 SIDS Category II : Infant deaths that meet					
	Category I except for one or more features.					
11.:						
11.						
11.4						
11.						
11.						
	11.91 Unclassified Sudden Infant Death					
	11.92 Other Unknown/Undetermined					
	11.92 Other Unknown/Undetermined					
	11.92 Other Unknown/Undetermined					
	PSANZ-NDC					
	PSANZ-NDC Igenital Abnormality (including terminations for					
cor	PSANZ-NDC Igenital Abnormality (including terminations for genital abnormalities)					
cor 1.1	PSANZ-NDC Igenital Abnormality (including terminations for genital abnormalities) Central nervous system					
1.1 1.2	PSANZ-NDC Igenital Abnormality (including terminations for genital abnormalities) Central nervous system Cardiovascular system					
1.1 1.2 1.3	PSANZ-NDC Igenital Abnormality (including terminations for genital abnormalities) Central nervous system Cardiovascular system Urinary system					
1.1 1.2 1.3 1.4	PSANZ-NDC Igenital Abnormality (including terminations for genital abnormalities) Central nervous system Cardiovascular system Urinary system Gastrointestinal system					
1.1 1.2 1.3 1.4 1.5	PSANZ-NDC Igenital Abnormality (including terminations for genital abnormalities) Central nervous system Cardiovascular system Urinary system Gastrointestinal system Chromosomal					
1.1 1.2 1.3 1.4 1.5 1.6	PSANZ-NDC Igenital Abnormality (including terminations for genital abnormalities) Central nervous system Cardiovascular system Urinary system Gastrointestinal system Chromosomal Metabolic					
1.1 1.2 1.3 1.4 1.5 1.6 1.7	PSANZ-NDC Igenital Abnormality (including terminations for genital abnormalities) Central nervous system Cardiovascular system Urinary system Gastrointestinal system Chromosomal Metabolic Multiple/non chromosomal syndromes					
1.1 1.2 1.3 1.4 1.5 1.6	PSANZ-NDC Igenital Abnormality (including terminations for genital abnormalities) Central nervous system Cardiovascular system Urinary system Gastrointestinal system Chromosomal Metabolic Multiple/non chromosomal syndromes Other congenital abnormality					
1.1 1.2 1.3 1.4 1.5 1.6 1.7	PSANZ-NDC Igenital Abnormality (including terminations for genital abnormalities) Central nervous system Cardiovascular system Urinary system Gastrointestinal system Chromosomal Metabolic Multiple/non chromosomal syndromes Other congenital abnormality 1.81 Musculoskeletal					
1.1 1.2 1.3 1.4 1.5 1.6 1.7	PSANZ-NDC Igenital Abnormality (including terminations for genital abnormalities) Central nervous system Cardiovascular system Urinary system Gastrointestinal system Chromosomal Metabolic Multiple/non chromosomal syndromes Other congenital abnormality 1.81 Musculoskeletal 1.82 Respiratory					
1.1 1.2 1.3 1.4 1.5 1.6 1.7	PSANZ-NDC Igenital Abnormality (including terminations for genital abnormalities) Central nervous system Cardiovascular system Urinary system Gastrointestinal system Chromosomal Metabolic Multiple/non chromosomal syndromes Other congenital abnormality 1.81 Musculoskeletal 1.82 Respiratory 1.83 Diaphragmatic hernia					
1.1 1.2 1.3 1.4 1.5 1.6 1.7	PSANZ-NDC Igenital Abnormality (including terminations for genital abnormalities) Central nervous system Cardiovascular system Urinary system Gastrointestinal system Chromosomal Metabolic Multiple/non chromosomal syndromes Other congenital abnormality 1.81 Musculoskeletal 1.82 Respiratory 1.83 Diaphragmatic hernia 1.84 Haematological					
1.1 1.2 1.3 1.4 1.5 1.6 1.7	PSANZ-NDC Igenital Abnormality (including terminations for genital abnormalities) Central nervous system Cardiovascular system Urinary system Gastrointestinal system Chromosomal Metabolic Multiple/non chromosomal syndromes Other congenital abnormality 1.81 Musculoskeletal 1.82 Respiratory 1.83 Diaphragmatic hemia 1.84 Haematological 1.85 Tumours					
cor 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8	PSANZ-NDC Igenital Abnormality (including terminations for genital abnormalities) Central nervous system Cardiovascular system Urinary system Gastrointestinal system Chromosomal Metabolic Multiple/non chromosomal syndromes Other congenital abnormality 1.81 Musculoskeletal 1.82 Respiratory 1.83 Diaphragmatic hemia 1.84 Haematological 1.85 Tumours 1.86 Other specified congenital abnormality					
1.1 1.2 1.3 1.4 1.5 1.6 1.7	PSANZ-NDC Igenital Abnormality (including terminations for genital abnormalities) Central nervous system Cardiovascular system Urinary system Gastrointestinal system Chromosomal Metabolic Multiple/non chromosomal syndromes Other congenital abnormality 1.81 Musculoskeletal 1.82 Respiratory 1.83 Diaphragmatic hemia 1.84 Haematological 1.85 Tumours					
cor 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8	PSANZ-NDC Igenital Abnormality (including terminations for genital abnormalities) Central nervous system Cardiovascular system Urinary system Gastrointestinal system Chromosomal Metabolic Multiple/non chromosomal syndromes Other congenital abnormality 1.81 Musculoskeletal 1.82 Respiratory 1.83 Diaphragmatic hemia 1.84 Haematological 1.85 Tumours 1.88 Other specified congenital abnormality Unspecified congenital abnormality					
1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8	PSANZ-NDC Igenital Abnormality (including terminations for genital abnormalities) Central nervous system Cardiovascular system Urinary system Gastrointestinal system Chromosomal Metabolic Multiple/non chromosomal syndromes Other congenital abnormality 1.81 Musculoskeletal 1.82 Respiratory 1.83 Diaphragmatic hemia 1.84 Haematological 1.85 Tumours 1.86 Other specified congenital abnormality					
1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 Ext ges 2.1	PSANZ-NDC Igenital Abnormality (including terminations for genital abnormalities) Central nervous system Cardiovascular system Gastrointestinal system Chromosomal Metabolic Multiple/non chromosomal syndromes Other congenital abnormality 1.81 Musculoskeletal 1.82 Respiratory 1.83 Diaphragmatic hemia 1.84 Haematological 1.85 Tumours 1.86 Other specified congenital abnormality Unspecified congenital abnormality					
1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8	PSANZ-NDC genital Abnormality (including terminations for genital abnormalities) Central nervous system Cardiovascular system Urinary system Gastrointestinal system Chromosomal Metabolic Multiple/non chromosomal syndromes Other congenital abnormality 1.81 Musculoskeletal 1.82 Respiratory 1.83 Diaphragmatic hemia 1.84 Haematological 1.85 Tumours 1.88 Other specified congenital abnormality Unspecified congenital abnormality Unspecified congenital abnormality Teme Prematurity (typically infants of <=24 weeks tation or <=600g birthweight)					
1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 Ext ges 2.1	PSANZ-NDC Igenital Abnormality (including terminations for genital abnormalities) Central nervous system Cardiovascular system Urinary system Gastrointestinal system Chromosomal Metabolic Multiple/non chromosomal syndromes Other congenital abnormality 1.81 Musculoskeletal 1.82 Respiratory 1.83 Diaphragmatic hemia 1.84 Haematological 1.85 Tumours 1.88 Other specified congenital abnormality Unspecified congenital abnormality Unspecified congenital abnormality Immer Prematurity (typically infants of <=24 weeks tation or <=600g birthweight) Not resuscitated					
1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 Ext ges 2.1 2.2	PSANZ-NDC Igenital Abnormality (including terminations for genital abnormalities) Central nervous system Cardiovascular system Gastrointestinal system Gastrointestinal system Chromosomal Metabolic Multiple/non chromosomal syndromes Other congenital abnormality 1.81 Musculoskeletal 1.82 Respiratory 1.83 Diaphragmatic hemia 1.84 Haematological 1.85 Tumours 1.86 Other specified congenital abnormality Unspecified congenital abnormality Unspecified congenital abnormality Teme Prematurity (typically infants of <=24 weeks tation or <=600g birthweight) Not resuscitated Unsuccessful resuscitation					
1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 Ext ges 2.1 2.2 2.9	PSANZ-NDC Igenital Abnormality (including terminations for genital abnormalities) Central nervous system Cardiovascular system Gastrointestinal system Chromosomal Metabolic Multiple/non chromosomal syndromes Other congenital abnormality 1.81 Musculoskeletal 1.82 Respiratory 1.83 Diaphragmatic hernia 1.84 Haematological 1.85 Tumours 1.88 Other specified congenital abnormality Unspecified congenital abnormality Verme Prematurity (typically infants of <=24 weeks tation or <=600g birthweight) Not resuscitated Unsuccessful resuscitation Unspecified or not known whether resuscitation attempted					
1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 Ext ges 2.1 2.2 2.9	PSANZ-NDC Ingenital Abnormality (including terminations for genital abnormalities) Central nervous system Cardiovascular system Urinary system Gastrointestinal system Chromosomal Metabolic Multiple/non chromosomal syndromes Other congenital abnormality 1.81 Musculoskeletal 1.82 Respiratory 1.83 Diaphragmatic hemia 1.84 Haematological 1.85 Tumours 1.88 Other specified congenital abnormality Unspecified congenital abnormality Unspecified congenital abnormality Vereme Prematurity (typically infants of <=24 weeks tation or <=600g birthweight) Not resuscitated Unsuccessful resuscitation Unspecified or not known whether resuscitation attempted dio-Respiratory Disorders					
1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 Ext ges 2.1 2.2 2.9	PSANZ-NDC Igenital Abnormality (including terminations for genital abnormalities) Central nervous system Cardiovascular system Urinary system Gastrointestinal system Chromosomal Metabolic Multiple/non chromosomal syndromes Other congenital abnormality 1.81 Musculoskeletal 1.82 Respiratory 1.83 Diaphragmatic hemia 1.84 Haematological 1.85 Tumours 1.88 Other specified congenital abnormality Unspecified congenital abnormality Unspecified congenital abnormality Verme Prematurity (typically infants of <=24 weeks tation or <=600g birthweight) Not resuscitated Unsuccessful resuscitation Unspecified or not known whether resuscitation attempted dio-Respiratory Disorders Hyaline membrane disease / Respiratory distress					
1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 Ext geg 2.1 2.2 2.9	PSANZ-NDC Igenital Abnormality (including terminations for genital abnormalities) Central nervous system Cardiovascular system Gastrointestinal system Chromosomal Metabolic Multiple/non chromosomal syndromes Other congenital abnormality 1.81 Musculoskeletal 1.82 Respiratory 1.83 Diaphragmatic hernia 1.84 Haematological 1.85 Tumours 1.88 Other specified congenital abnormality Unspecified congenital abnormality Unspecified congenital abnormality Perme Prematurity (typically infants of <=24 weeks tation or <=600g birthweight) Not resuscitated Unsuccessful resuscitation Unspecified or not known whether resuscitation attempted dio-Respiratory Disorders Hyaline membrane disease / Respiratory distress syndrome (RDS)					
1.9 Ext ges 2.1 2.2 2.9 Car 3.1 3.2	PSANZ-NDC Ingenital Abnormality (including terminations for genital abnormality) Central nervous system Cardiovascular system Urinary system Gastrointestinal system Chromosomal Metabolic Multiple/non chromosomal syndromes Other congenital abnormality 1.81 Musculoskeletal 1.82 Respiratory 1.83 Diaphragmatic hemia 1.84 Haematological 1.85 Tumours 1.88 Other specified congenital abnormality Unspecified congenital abnormality Unspecified congenital abnormality Unspecified congenital abnormality Unspecified or not known whether resuscitation Unspecified or not known whether resuscitation attempted dio-Respiratory Disorders Hyaline membrane disease / Respiratory distress syndrome (RDS) Meconium aspiration syndrome					
1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 Ext ges 2.1 2.2 2.9 Can 3.1	PSANZ-NDC Igenital Abnormality (including terminations for genital abnormalities) Central nervous system Cardiovascular system Urinary system Gastrointestinal system Chromosomal Metabolic Multiple/non chromosomal syndromes Other congenital abnormality 1.81 Musculoskeletal 1.82 Respiratory 1.83 Diaphragmatic hemia 1.84 Haematological 1.85 Tumours 1.88 Other specified congenital abnormality Unspecified congenital abnormality Unspecified congenital abnormality Verme Prematurity (typically infants of <=24 weeks tation or <=600g birthweight) Not resuscitated Unsuccessful resuscitation Unspecified or not known whether resuscitation attempted dio-Respiratory Disorders Hyaline membrane disease / Respiratory distress syndrome (RDS) Meconium aspiration syndrome Primary persistent pulmonary hypertension					
1.9 Ext ges 2.1 2.2 2.9 Car 3.1 3.2	PSANZ-NDC Ingenital Abnormality (including terminations for genital abnormality) Central nervous system Cardiovascular system Urinary system Gastrointestinal system Chromosomal Metabolic Multiple/non chromosomal syndromes Other congenital abnormality 1.81 Musculoskeletal 1.82 Respiratory 1.83 Diaphragmatic hemia 1.84 Haematological 1.85 Tumours 1.88 Other specified congenital abnormality Unspecified congenital abnormality Unspecified congenital abnormality Unspecified congenital abnormality Unspecified or not known whether resuscitation Unspecified or not known whether resuscitation attempted dio-Respiratory Disorders Hyaline membrane disease / Respiratory distress syndrome (RDS) Meconium aspiration syndrome					

bronchopulmonary dysplasia)

Pulmonary haemorrhage

Pneumothorax

Spontaneous preterm with membrane rupture of unknown

duration before delivery

11

2

3

36

3.7

3.8 Other

1	Infection		
	4.1	Bacte	rial
		4.11	Congenital bacterial
			4.111 Group B Streptococcus
			4.112 E coli
			4.113 Lysteria monocytogenes
			4.114 Spirochaetal, eg syphilis
			4.118 Other bacterial
			4.119 Unspecified bacterial
		4.12	Acquired bacterial
			4.121 Group B Streptococcus
			4.122 E coli
			4.125 Other Gram negative bacilli (other than
			coli)
			4.126 Staphylococcus aureus
			4.127 Coagulase negative Staphylococcus 4.128 Other specified bacterial
			4.129 Unspecified bacterial
	4.2	Viral	4. 129 Onspecified bacterial
	4.2	4.21	Congenital viral
		7.21	4.211 Cytomegalovirus
			4.213 Herpes simplex virus
			4.214 Rubella virus
			4.218 Other specified viral
			4.219 Unspecified viral
		4.22 A	Acquired viral
			4.221 Cytomegalovirus
			4.223 Herpes simplex virus
			4.224 Rubella virus
			4.228 Other specified viral
			4.229 Unspecified viral
	4.3		zoal e.g. Toxoplasma
	4.5	Funga	
	4.8		specified organism
	4.9 U	nspecif	fied organism
5		ologica	
	5.1	Нурох	kic ischaemic encephalopathy / Perinatal
			xia (typically infants of >24 weeks gestation or
	5.2		g birthweight) ranial haemorrhage
	5.2		Intraventricular Haemorrhage
			Subgaleal Haemorrhage
			Subarachnoid Haemorrhage
			Subdural Haemorrhage
			Other Intracranial Haemorrhage
	5.8	Other	
6		rointes	
	6.1		tising enterocolitis
	6.8	Other	
7	Other		
	7.1		en Infant Death Syndrome (SIDS)
		7.11	SIDS Category IA: Classic features of SIDS
			present and completely documented.
		7.12	SIDS Category IB: Classic features of SIDS
		•	present but incompletely documented.
		7.13	SIDS Category II : Infant deaths that meet
			category I except for one or more features.
	7.2		ystem failure
		7.21	Secondary to intrauterine growth restriction
		7.28	
		7.29	Unspecified/undetermined primary cause or
		_	trigger event
			na
	7.3	Traun	
	7.3	7.31	Accidental
	7.3	7.31 7.32	Non accidental
		7.31 7.32 7.39	Non accidental Unspecified
	7.3 7.4	7.31 7.32 7.39 Treat	Non accidental Unspecified ment complications
		7.31 7.32 7.39 Treati 7.41	Non accidental Unspecified ment complications Surgical
	7.4	7.31 7.32 7.39 Treat 7.41 7.42	Non accidental Unspecified ment complications Surgical Medical
	7.4 7.8	7.31 7.32 7.39 Treatr 7.41 7.42 Other	Non accidental Unspecified ment complications Surgical Medical specified
	7.4	7.31 7.32 7.39 Treate 7.41 7.42 Other Unknown	Non accidental Unspecified ment complications Surgical Medical specified own/Undetermined
	7.4 7.8	7.31 7.32 7.39 Treatr 7.41 7.42 Other	Non accidental Unspecified ment complications Surgical Medical specified

examined